Immatics (NASDAQ:IMTX) Shares Gap Up – What’s Next?

Posted by Brian Himes on Aug 27th, 2026

Immatics N.V. (NASDAQ:IMTX – Get Free Report) shares gapped up prior to trading on Tuesday . The stock had previously closed at $8.69, but opened at $9.59. Immatics shares last traded at $9.59, with a volume of 167,701 shares changing hands.

Wall Street Analysts Forecast Growth

Several analysts recently weighed in on IMTX shares. Wall Street Zen downgraded Immatics from a “hold” rating to a “sell” rating in a research report on Saturday, May 2nd. Chardan Capital reissued a “buy” rating and set a $25.00 target price on shares of Immatics in a research note on Tuesday, May 19th. Weiss Ratings cut shares of Immatics from a “sell (d)” rating to a “sell (d-)” rating in a report on Tuesday, June 23rd. Finally, Jefferies Financial Group set a $17.00 price target on shares of Immatics in a report on Tuesday. Six analysts have rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat, Immatics presently has a consensus rating of “Moderate Buy” and a consensus price target of $20.60.

Read Our Latest Stock Analysis on IMTX

Immatics Stock Up 2.1%

The stock has a market capitalization of $1.26 billion, a price-to-earnings ratio of -5.07 and a beta of 1.33. The stock has a 50 day moving average price of $9.46 and a 200 day moving average price of $10.04.

Immatics (NASDAQ:IMTX – Get Free Report) last issued its quarterly earnings data on Tuesday, August 18th. The company reported ($0.53) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.47) by ($0.06). Immatics had a negative net margin of 495.71% and a negative return on equity of 47.41%. The business had revenue of $10.44 million during the quarter, compared to the consensus estimate of $12.42 million. Sell-side analysts forecast that Immatics N.V. will post -2 earnings per share for the current fiscal year.

Institutional Trading of Immatics

A number of institutional investors and hedge funds have recently bought and sold shares of IMTX. Bank of America Corp DE lifted its holdings in Immatics by 166.0% during the 4th quarter. Bank of America Corp DE now owns 3,575 shares of the company’s stock worth $25,000 after buying an additional 2,231 shares during the period. Quarry LP bought a new stake in shares of Immatics in the 4th quarter valued at $84,000. Engineers Gate Manager LP bought a new position in Immatics during the second quarter worth $124,000. Fox Run Management L.L.C. acquired a new position in Immatics in the fourth quarter valued at $129,000. Finally, Graham Capital Management L.P. acquired a new position in Immatics in the fourth quarter valued at $206,000. 64.41% of the stock is currently owned by institutional investors and hedge funds.

Immatics Company Profile

(Get Free Report)

Immatics N.V. (NASDAQ: IMTX) is a clinical-stage biotechnology company dedicated to the development of T cell receptor (TCR)-based immunotherapies for solid tumors. The company leverages its proprietary discovery and engineering platforms to identify tumor-specific peptide targets and develop therapies that harness the power of a patient’s immune system. Immatics’ approach aims to generate durable responses by guiding T cells to recognize and kill cancer cells with high precision.

At the core of Immatics’ technology suite is the XPRESIDENT® platform, which mines the cancer peptidome to uncover novel tumor antigens naturally presented on the surface of cancer cells.